NEW YORK (TheStreet) -- The broader market closed near the highs of the day ahead of the statement from the Federal Reserve at the end of the FOMC meeting Wednesday.
On CNBC's "Fast Money" TV show, Guy Adami said the Fed has to do something at this point. He is expecting $10 billion to $15 billion in bond tapering. He added that Caterpillar (CAT) looks like a good short.
Brian Kelly concurred on Caterpillar and added that the risk-to-reward for holding large positions into Wednesday's FOMC meeting are not favorable.
Jim Lebenthal is a Caterpillar bull, but said he wouldn't be surprised to see some profit-taking. Karen Finerman said she's not trying to trade around the Fed since it is too hard. She added that what she owns now she'll likely want to own in a month from now, regardless of the Fed. Mike Khouw said that with Fed Chairman Ben Bernanke stepping down soon, he would be surprised if some sort of tapering was not initiated. However, he did say the economic numbers have not been that good and inflation hasn't moved much. Jon Hilsenrath of the Wall Street Journal was a guest on the show and said the Fed is in a pickle because of its forecasts of both lower unemployment and low interest rates. In a healthy economy, the two do not typically coexist, he suggested. He added that the Fed doesn't want to upset the market, which may or may not cause the central bank to taper, since the market seems to expect about $10 billion per month in tapering efforts. Many Fed officials are on the fence. Adobe (ADBE) reported earnings and Adami said he would rather be taking profits than buying the stock. Even though Qualcomm (QCOM) is near a 52-week high, Adami said he still considers the stock a buy. Lebenthal called it a cash machine and thinks it will rip right through $70 to the upside. Kelly added that if that happens, $100 per share is not out of the question. General Motors (GM) announced it was working on a long-range electric car that is $50,000 less than Tesla Motors' (TSLA) Model S, making the former stock an ideal fit for the show's "Street Fight" segment.
5 Best Stocks To Buy Right Now: Pansoft Company Limited(PSOF)
Pansoft Company Limited engages in the development and marketing of accounting and enterprise resource planning software primarily for the oil and gas industry in the People?s Republic of China. It offers software solutions in various business operations, including accounting, order processing, shipping, invoicing, inventory control, and customer relationship management. The company?s products comprise PanBI, a platform for business data analysis, model building, statements processing, and data storage building; PanXI, a database management platform, which converts business operational data into accounting systems and used in generating financial documents; PanMM, a supply chain management software for large enterprises; and PanSchema, a development platform that focuses on management information products. It also provides various services, including software systems development, software integration, software compatibility enhancement, functionality expansion, and busin ess process reengineering, as well as support, training, maintenance, and execution client services. The company was formerly known as Time Maker Limited and changed its name to Pansoft Company Limited in March 2006. Pansoft Company Limited was founded in 2001 and is headquartered in Jinan, China. Pansoft Company Limited operates as a subsidairy of Timesway Group, Ltd.
5 Best Stocks To Buy Right Now: Boston Scientific Corp (BSX)
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. During the year ended December 31, 2011, its products were offered for sale by seven core businesses: Interventional Cardiology, CRM, Endoscopy, Peripheral Interventions, Urology/Women�� Health, Neuromodulation, and Electrophysiology. In January 2011, it completed the acquisition of Intelect Medical, Inc. In January 2011, it completed the acquisition of Sadra Medical, Inc. In March 2011, the Company completed the acquisition of Atritech, Inc. In February 2011, it announced the acquisitions of S.I. Therapies and ReVascular Therapeutics, Inc. In January 2011, the Company sold its Neurovascular business to Stryker Corporation. In June 2012, the Company acquired Cameron Health, Inc. of San Clemente, California and, as a result, added to its product portfolio subcutaneous implantable cardioverter defibrillator, called the S-ICD System.
Interventional Cardiology
The Company offers coronary stent product. Coronary stents are tiny, mesh tubes used in the treatment of coronary artery disease, which are implanted in patients to prop open arteries and facilitate blood flow to and from the heart. The Company offers a two-drug platform strategy with its paclitaxel-eluting and everolimus-eluting stent system offerings, and it offers a range of stent sizes. The Company markets its next-generation internally-developed and self-manufactured PROMUS Element stent system in the United States, its Europe/Middle East/Africa (EMEA) region and certain Inter-Continental countries, including China and India. It markets the PROMUS everolimus-eluting stent system, supplied to the Company by Abbott Laboratories, in Japan. It also markets its TAXUS paclitaxel-eluting stent line, including its third-generation TAXUS Element paclitaxel-eluting stent system in the U.nited States, Japan, EMEA and certain Inter-Continental countries.
The Compa! ny markets a line of products used to treat patients with atherosclerosis, a principal cause of coronary artery obstructive disease. Its product offerings include balloon catheters, rotational atherectomy systems, guide wires, guide catheters, embolic protection devices, and diagnostic catheters used in percutaneous transluminal coronary angioplasty (PTCA). The Company markets a family of intraluminal catheter-directed ultrasound imaging catheters and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels. The iLab Ultrasound Imaging System continues as its flagship console and is compatible with its line of imaging catheters. The system is designed to enhance the diagnosis and treatment of blocked vessels and heart disorders. Sadra is developing a repositionable and retrievable device for transcatheter aortic valve replacement (TAVR) to treat patients with severe aortic stenosis. The Lotus Valve System consists of a stent-mounted tissue valve prosthesis and catheter delivery system for guidance and placement of the valve. Atritech has developed a device designed to close the left atrial appendage in patients with atrial fibrillation who are at risk for ischemic stroke. The WATCHMAN Left Atrial Appendage Closure Technology, developed by Atritech, is the first device proven in a randomized clinical trial to offer an alternative to anticoagulant drugs, and is approved for use in CE Mark countries.
Cardiac Rhythm Management
The Company develops, manufactures and markets a variety of implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, including Implantable cardioverter defibrillator (ICD) systems used to detect and treat abnormally fast heart rhythms (tachycardia) that could result in sudden cardiac death, including implantable cardiac resynchronization therapy defibrillator (CRT-D) systems used to treat heart failure, and implantable pacemaker systems used to manage slow or irregular heart rhyth! ms (brady! cardia), including implantable cardiac resynchronization therapy pacemaker (CRT-P) systems used to treat heart failure. Its product offerings include its COGNIS cardiac resynchronization therapy defibrillator (CRT-D), its TELIGEN ICD systems and its ALTRUA family of pacemaker systems. During 2011, it began the United States launch of its next-generation line of defibrillators, INCEPTA, ENERGEN and PUNCTUA.
Endoscopy
The Company markets a range of products to diagnose, treat and ease a variety of digestive diseases, including those affecting the esophagus, stomach, liver, pancreas, duodenum, and colon. Common disease states include esophagitis, portal hypertension, peptic ulcers as well as esophageal, biliary, pancreatic and colonic cancer. The Company offers the Radial Jaw 4 Single-Use Biopsy Forceps, which are designed to enable collection of large high-quality tissue specimens without the need to use large channel therapeutic endoscopes. Its exclusive line of RX Biliary System devices are designed to provide greater access and control for physicians to diagnose and treat challenging conditions of the bile ducts, such as removing gallstones, opening obstructed bile ducts and obtaining biopsies in suspected tumors. The Company also markets the Spyglass Direct Visualization System for direct imaging of the pancreatico-biliary system. The Spyglass System is a single-operator cholangioscopy device that offers clinicians a direct visualization of the pancreatico-biliary system and includes supporting devices for tissue acquisition, stone management and lithotripsy. Its products also include the WallFlex family of stents, in particular, the WallFlex Biliary line and WallFlex Esophageal line; and in 2011, the Company launched its Advanix Biliary Plastic Stent System and the Expect Endoscopic Ultrasound Aspiration Needle in the United States and certain international markets. Its Resolution Clip Device is an endoscopic mechanical clip designed to treat gastrointestinal bleeding.
T! he Company markets devices to diagnose, treat and ease pulmonary disease systems within the airway and lungs. Its products are designed to help perform biopsies, retrieve foreign bodies from the airway, open narrowings of an airway, stop internal bleeding, and ease symptoms of some types of airway cancers. Its product line includes pulmonary biopsy forceps, transbronchial aspiration needles, cytology brushes and tracheobronchial stents used to dilate narrowed airway passages or for tumor management. Asthmatx, Inc. designs, manufactures and markets a less-invasive, catheter-based bronchial thermoplasty procedure for the treatment of severe persistent asthma. The Alair Bronchial Thermoplasty System, developed by Asthmatx, has both CE Mark and Food and Drug Administration (FDA) approval and is the first device-based asthma treatment approved by the FDA.
Peripheral Interventions
The Company sells various products designed to treat patients with peripheral disease, including a line of medical devices used in percutaneous transluminal angioplasty and peripheral vascular stenting. Its peripheral product offerings include stents, balloon catheters, wires, peripheral embolization devices and vena cava filters. In 2010 and 2011, it launched several of its products internationally, including the EPIC self-expanding nitinol stent system in certain international markets, and the Carotid WALLSTENT stent system in Japan. The Company launched three new peripheral angioplasty balloons in 2011, including its next-generation Mustang percutaneous transluminal angioplasty (PTA) balloon, its Coyote balloon catheter, a highly deliverable and ultra-low profile balloon dilatation catheter designed for a range of peripheral angioplasty procedures and its Charger PTA Balloon Catheter, a 0.035 inch percutaneous transluminal angioplasty balloon catheter designed for post-stent dilatation, as well as conventional balloon angioplasty to open blocked peripheral arteries. The Company has commenced a limited ma! rket rele! ase of its OFFROAD re-entry catheter system in certain international markets, and in February 2012, it launched its TRUEPATH intraluminal CTO device in the United States.
The Company sells products designed to treat patients with non-vascular disease. Its non-vascular suite of products include biliary stents, drainage catheters and micro-puncture sets designed to treat, diagnose and ease various forms of benign and malignant tumors. The Company continues to market its extensive line of Interventional Oncology product solutions, including the Renegade HI-FLO Fathom microcatheter and guidewire system and Interlock - 35 Fibered IDC Occlusion System for peripheral embolization. The Company�� FilterWire EZ Embolic Protection System is a filter designed to capture embolic material that may become dislodged during a procedure, which could otherwise travel into the microvasculature where it could cause a heart attack or stroke. It is commercially available in the United States, its EMEA region and certain Inter-Continental countries for multiple indications, including the treatment of disease in peripheral, coronary and carotid vessels. It is also available in the United States for the treatment of saphenous vein grafts and carotid artery stenting procedures.
Urology/Women�� Health
The Company�� Urology/Women�� Health division develops, manufactures and sells devices to treat various urological and gynecological disorders. The Company sells a variety of products designed to treat patients with urinary stone disease, stress urinary incontinence, pelvic organ prolapse and excessive uterine bleeding. The Company offers a line of stone management products, including ureteral stents, wires, lithotripsy devices, stone retrieval devices, sheaths, balloons and catheters.
The Company markets a range of devices for the treatment of conditions, such as female urinary incontinence, pelvic floor reconstruction (rebuilding of the anatomy to its original state), and ! menorrhag! ia (excessive menstrual bleeding). It offers a breadth of mid-urethral sling products, sling materials, graft materials, pelvic floor reconstruction kits, and suturing devices. The Company markets its Genesys Hydro ThermAblator (HTA) system, a next-generation endometrial ablation system designed to ablate the endometrial lining of the uterus in premenopausal women with menorrhagia. The Genesys HTA System features a smaller and lighter console, simplified set-up requirements, and an enhanced graphic user interface and is designed to improve operating performance.
Neuromodulation
The Company within its Neuromodulation business markets the Precision Spinal Cord Stimulation (SCS) system, used for the management of chronic pain. In 2011, the Company launched its Clik Anchor for its Precision Plus SCS System, a rechargeable SCS device for chronic pain management. During 2011, it received FDA approval for and launched the Infinion 16 Percutaneous Lead, a 16-contact percutaneous lead. The Company also markets the Linear 3-4 and Linear 3-6 Percutaneous Leads for use with its SCS systems, which are designed to provide physicians more treatment options for their chronic pain patients. Intelect Medical, Inc. is a development-stage company developing advanced visualization and programming for the Vercise system.
Electrophysiology
The Company within its Electrophysiology business develops less-invasive medical technologies used in the diagnosis and treatment of rate and rhythm disorders of the heart. Included in its product offerings are radio frequency (RF) generators, steerable RF ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, and other accessories. Its products include the Blazer and Blazer Prime line of temperature ablation catheters, designed to deliver enhanced performance, responsiveness, and durability. Its cooled ablation portfolio includes the closed-loop irrigated catheter on the market, the Chilli II cooled! ablation! catheter, and the newly launched Blazer Open-Irrigated ablation catheter with a Total Tip Cooling Design.
The Company competes with Abbott Laboratories, Medtronic, Inc., St. Jude Medical, Inc. and Johnson & Johnson.
Advisors' Opinion: - [By Keith Speights]
Has anyone noticed a common theme among the first-quarter results for many of the big medical-device companies? In case you missed earnings announcements from Abbott Labs (NYSE: ABT ) , Boston Scientific (NYSE: BSX ) , Edwards Lifesciences (NYSE: EW ) , Johnson & Johnson (NYSE: JNJ ) , or Stryker (NYSE: SYK ) , the following chart shows how their medical-device business fared during the quarter.
Kesa Electricals plc, through its subsidiaries, engages in retailing electrical products. The company offers products in three categories: white, brown, and grey electrical goods and related accessories. The white category goods comprise large and small sized domestic appliances, such as refrigerators, washing machines, microwaves, coffee machines, and irons. The brown category goods include various vision and audio products consisting of flat-screen televisions, DVD players, MP3 players, and camcorders The grey category goods comprise telecommunications and multimedia products, including mobile telephones, personal computers, laptops, digital cameras, printers, scanners, games, and electronics. The company also provides various associated services, which include home delivery and installation, and credit and extended warranties. It operates approximately 700 stores under the brand names of DARTY, Comet, BCC, Vanden Borre, and Datart in France, the United Kingdom, Belgium , Holland, the Czech Republic, Slovakia, Italy, Luxembourg, Turkey, and Spain. Kesa Electricals plc is based in London, the United Kingdom.
5 Best Stocks To Buy Right Now: Electro Rent Corporation(ELRC)
Electro Rent Corporation engages in the rental, lease, and sale of new and used electronic test and measurement equipment. Its equipment portfolio consists of general purpose test and measurement instruments; personal computers, workstations, and servers; and electrical test equipment and inspection equipment. The company rents or leases its equipment primarily to companies operating in the aerospace, defense, telecommunications, electronics, and semiconductor industries. Electro Rent Corporation serves its customers through sales offices, and calibration and service centers in the United States, Canada, China, and Europe. The company was founded in 1965 and is headquartered in Van Nuys, California.
Advisors' Opinion: - [By Seth Jayson]
Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Electro Rent (Nasdaq: ELRC ) , whose recent revenue and earnings are plotted below.
5 Best Stocks To Buy Right Now: Yoma Strategic Holdings Ltd (Z59.SI)
Yoma Strategic Holdings Ltd., an investment holding company, engages in the development and management of properties, and sale of land development rights and houses in Singapore, Myanmar, and the People�s Republic of China. It is also involved in agricultural activities, such as the managing and marketing produce from a 100,000 acre Jatropha Curcas and black pepper plantation located in the Ayerwaddy Division of Myanmar; and automobile dealership business, as well as provision of construction related services. In addition, the company provides project management services; property management; and architectural and design services. The company�s development properties portfolio includes apartments, condominiums, private residential properties, houses, and townhouses. Yoma Strategic Holdings Ltd. is based in Singapore.